Nivolumab‑induced cholangitis in patients with non‑small cell lung cancer: Case series and a review of literature
Abstract
Immune checkpoint inhibitors (ICIs), including nivolumab, have exhibited substantial benefits in the treatment of several types of cancers. However, treatment with ICIs is often accompanied by immune‑related adverse events (irAEs), and a clear understanding of the precise indications and management of irAEs is important for harnessing the full potential of these agents. While skin‑ or gastrointestinal‑associated irAEs have been relatively well...
Paper Details
Title
Nivolumab‑induced cholangitis in patients with non‑small cell lung cancer: Case series and a review of literature
Published Date
Sep 18, 2019
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History